InsiderTrades.com logo

MDNA Insider Trading

Insider Ownership Percentage: 22.57%
Insider Buying (Last 12 Months): C$11,200.00
Insider Selling (Last 12 Months): C$0.00

Medicenna Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Medicenna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medicenna Therapeutics Share Price & Price History

Current Price: C$0.45
Price Change: ▼ Price Decrease of -0.005 (-1.11%)
As of 10/8/2026 03:50 PM ET

This chart shows the closing price history over time for MDNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Medicenna Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2025David HymanInsiderBuy10,000C$1.12C$11,200.0050,000
2/13/2025Albert George BeraldoDirectorBuy500C$1.29C$645.00
1/9/2025David HymanSenior OfficerBuy20,000C$1.45C$29,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Medicenna Therapeutics (TSE:MDNA)

0.43% of Medicenna Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Medicenna Therapeutics logo
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company's most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors using its proprietary BiSKIT and T-MASK platforms.
Read More on Medicenna Therapeutics

Today's Range

Now: C$0.45
Low: C$0.43
High: C$0.46

50 Day Range

MA: C$0.42
Low: C$0.36
High: C$0.48

52 Week Range

Now: C$0.45
Low: C$0.34
High: C$1.97

Volume

44,681 shs

Average Volume

86,892 shs

Market Capitalization

C$41.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.926431

Who are the company insiders with the largest holdings of Medicenna Therapeutics?

Medicenna Therapeutics' top insider investors include:
  1. Albert George Beraldo (Director)
  2. David Hyman (Insider)
  3. Elizabeth Williams (Senior Officer)
  4. Chandra Panchal (Director)
  5. David Hyman (Senior Officer)
Learn More about top insider investors at Medicenna Therapeutics.